Payment overview · 2025
General Payments
$184.48
10 reported records · 6 companies
Healthcare provider profile · identity verified
Robert Ray Johnson, MD
Allopathic & Osteopathic Physicians|Family Medicine · LELAND, NC · NPI 1982780722
Verified facts
What the public records show
CMS Open Payments records show Robert Ray Johnson, MD received $184.48 in general payments during 2025 across 10 reported records.
Novo Nordisk Inc accounted for 21.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $39.43 | 21.4% | 2 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.03 | 20.6% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $35.51 | 19.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.86 | 17.3% | 2 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $23.07 | 12.5% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.58 | 9.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $184.48 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ALVESCO Normalized: alvesco |
Drug | Azurity Pharmaceuticals, Inc. | $38.03 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $35.51 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $31.86 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.86 | 2 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $23.07 | 1 | 2025 |
Source payment records
|
|||||
| MENQUADFI Normalized: menquadfi |
Biological | SANOFI PASTEUR INC. | $23.07 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | SANOFI PASTEUR INC. | $23.07 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.59 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.84 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.84 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $16.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 377 | 112 |
| Levothyroxine Sodium | Levothyroxine Sodium | 247 | 63 |
| Amlodipine Besylate | Amlodipine Besylate | 246 | 77 |
| Losartan Potassium | Losartan Potassium | 223 | 64 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 171 | 51 |
| Gabapentin | Gabapentin | 149 | 46 |
| Omeprazole | Omeprazole | 140 | 38 |
| Ezetimibe | Ezetimibe | 138 | 42 |
| Pioglitazone Hcl | Pioglitazone Hcl | 138 | 42 |
| Pregabalin | Pregabalin | 132 | 28 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 119 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 118 | 40 |
| Tramadol Hcl | Tramadol Hcl | 117 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 115 | 33 |
| Metformin Hcl | Metformin Hcl | 113 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 112 | 34 |
| Oxycodone Hcl | Oxycodone Hcl | 109 | 14 |
| Lisinopril | Lisinopril | 102 | 35 |
| Alprazolam | Alprazolam | 99 | 23 |
| Morphine Sulfate Er | Morphine Sulfate | 93 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 92 | 28 |
| Simvastatin | Simvastatin | 92 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 88 | 27 |
| Furosemide | Furosemide | 74 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 72 | 22 |
| Synthroid | Levothyroxine Sodium | 67 | 15 |
| Trazodone Hcl | Trazodone Hcl | 66 | 25 |
| Metformin Hcl Er | Metformin Hcl | 65 | 23 |
| Carvedilol | Carvedilol | 64 | 22 |
| Montelukast Sodium | Montelukast Sodium | 64 | 16 |
| Eliquis | Apixaban | 63 | 14 |
| Glimepiride | Glimepiride | 63 | 18 |
| Irbesartan | Irbesartan | 62 | 19 |
| Sertraline Hcl | Sertraline Hcl | 61 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 61 | 14 |
| Allopurinol | Allopurinol | 60 | 19 |
| Jardiance | Empagliflozin | 60 | 15 |
| Chlorthalidone | Chlorthalidone | 56 | 16 |
| Buspirone Hcl | Buspirone Hcl | 55 | 12 |
| Potassium Chloride | Potassium Chloride | 53 | 18 |
| Clonazepam | Clonazepam | 51 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 50 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 49 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 47 | 15 |
| Finasteride | Finasteride | 46 | suppressed |
| Celecoxib | Celecoxib | 45 | 15 |
| Farxiga | Dapagliflozin Propanediol | 43 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 43 | suppressed |
| Bupropion Xl | Bupropion Hcl | 41 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 41 | 13 |
| Methadone Hcl | Methadone Hcl | 40 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 40 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | suppressed |
| Trulicity | Dulaglutide | 36 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | 13 |
| Eszopiclone | Eszopiclone | 35 | suppressed |
| Prednisone | Prednisone | 35 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 34 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 33 | 12 |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Topiramate | Topiramate | 33 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 32 | 13 |
| Felodipine Er | Felodipine | 32 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 31 | suppressed |
| Famotidine | Famotidine | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 29 | suppressed |
| Valsartan | Valsartan | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 28 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Meloxicam | Meloxicam | 27 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Temazepam | Temazepam | 26 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 22 |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Dutasteride | Dutasteride | 23 | suppressed |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Ozempic | Semaglutide | 23 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Cephalexin | Cephalexin | 21 | 17 |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 12 |
| Fentanyl | Fentanyl | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Testosterone | Testosterone | 20 | suppressed |
| Lorazepam | Lorazepam | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Febuxostat | Febuxostat | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Buprenorphine | Buprenorphine | 14 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | suppressed |
| Nateglinide | Nateglinide | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Trospium Chloride Er | Trospium Chloride | 14 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Repaglinide | Repaglinide | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Jantoven | Warfarin Sodium | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $184.48 · 10 records | Novo Nordisk Inc | ALVESCO, BEYFORTUS, BREZTRI, GVOKE HYPOPEN, MENQUADFI, OTEZLA, Ozempic, REPATHA, Rybelsus, VAXELIS, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error